. . . . . "Z(MSM0021627502)" . "359827" . "NL - Nizozemsko" . . "Alzheimer\u00B4s disease; cholinesterases; cholinesterase inhibitors"@en . "4" . "Komers, Karel" . "Cholinester\u00E1zy a cholinester\u00E1zov\u00E9 inhibitory"@cs . . . . . "1573-4080" . "Alzheimerova choroba je nejb\u011B\u017En\u011Bj\u0161\u00ED neurodegenerativn\u00ED onemocn\u011Bn\u00ED klinicky charakterizovan\u00E9 v\u00FDznamn\u00FDm poklesem kognitivn\u00EDch funkc\u00ED, ztr\u00E1tou pam\u011Bti a schopnosti se u\u010Dit, spole\u010Dn\u011B s poklesem schopnosti vykon\u00E1vat b\u011B\u017En\u00E9 denn\u00ED aktivity. V\u00FDznamn\u00FDmi neuropsychiatrick\u00FDmi symptomy jsou apatie, podr\u00E1\u017Ed\u011Bnost, deprese atd. Farmakoterapie Alzheimerovy choroby se za posledn\u00EDch deset let posunula od u\u017E\u00EDv\u00E1n\u00ED psychotropn\u00EDch l\u00E9\u010Div na uklidn\u011Bn\u00ED k l\u00E9\u010Div\u016Fm zam\u011B\u0159en\u00FDm na n\u00E1hradu neurotransmiter\u016F. Jenom jedna skupina l\u00E9\u010Div byla rozs\u00E1hle hodnocena v klinick\u00FDch studi\u00EDch s pacienty s Alzheimerovou chorobou a schv\u00E1lena FDA pro l\u00E9\u010Dbu Alzheimerovy choroby. Jsou to inhibitory cholinester\u00E1z, kter\u00E9 maj\u00ED v\u00FDznamn\u00FD vliv na stav kognitivn\u00EDch funkc\u00ED u pacient\u016F s Alzheimerovou chorobou."@cs . "Alzheimer\u00B4s disease is the most common neurodegenerative disorder, clinically characterized by a noticeable cognitive decline defined by a loss of memory and learning ability, together with a reduced ability to perform basic activities of daily living, and a diverse array of neuropsychiatric symptoms such as apathy, verbal and physical agitation, irritability, depression etc. Pharmacotherapy of Alzheimer\u00B4s disease has progressed in the past ten years from the use of psychotropic medications for sedation to the use of rational treatments aimed at neurotransmitter replacement. Only one class of medications has been extensively evaluated in clinical trials with patients with Alzheimer\u00B4s disease and is approved by the US Food and Drug Administration for Alzheimer\u00B4s disease treatment. These medications are cholinesterase inhibitors and have a significant, although modest, effect on the cognitive status of patients with Alzheimer\u00B4s disease." . . . "RIV/00216275:25310/08:00007777" . "2"^^ . . . "Cholinesterases and Cholinesterase Inhibitors"@en . "[D784D39448AB]" . "4" . "Cholinesterases and Cholinesterase Inhibitors" . "25310" . "RIV/00216275:25310/08:00007777!RIV09-MSM-25310___" . "2"^^ . . "Cholinesterases and Cholinesterase Inhibitors" . "Current Enzyme Inhibition" . "Cholinesterases and Cholinesterase Inhibitors"@en . "Alzheimer\u00B4s disease is the most common neurodegenerative disorder, clinically characterized by a noticeable cognitive decline defined by a loss of memory and learning ability, together with a reduced ability to perform basic activities of daily living, and a diverse array of neuropsychiatric symptoms such as apathy, verbal and physical agitation, irritability, depression etc. Pharmacotherapy of Alzheimer\u00B4s disease has progressed in the past ten years from the use of psychotropic medications for sedation to the use of rational treatments aimed at neurotransmitter replacement. Only one class of medications has been extensively evaluated in clinical trials with patients with Alzheimer\u00B4s disease and is approved by the US Food and Drug Administration for Alzheimer\u00B4s disease treatment. These medications are cholinesterase inhibitors and have a significant, although modest, effect on the cognitive status of patients with Alzheimer\u00B4s disease."@en . . "12"^^ . "\u0160t\u011Bp\u00E1nkov\u00E1, \u0160\u00E1rka" . "Cholinester\u00E1zy a cholinester\u00E1zov\u00E9 inhibitory"@cs .